Next Article in Journal
Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey
Next Article in Special Issue
NF-κB: A Druggable Target in Acute Myeloid Leukemia
Previous Article in Journal
Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies
Previous Article in Special Issue
Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
 
 
Review
Peer-Review Record

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

Cancers 2022, 14(14), 3456; https://doi.org/10.3390/cancers14143456
by Mila S. Griffioen, David C. de Leeuw, Jeroen J. W. M. Janssen and Linda Smit *
Reviewer 1:
Reviewer 2:
Cancers 2022, 14(14), 3456; https://doi.org/10.3390/cancers14143456
Submission received: 15 June 2022 / Accepted: 12 July 2022 / Published: 15 July 2022
(This article belongs to the Collection Acute Myeloid Leukemia (AML))

Round 1

Reviewer 1 Report

This is a superb review on venetoclax use in AML, its mechanism of action and resistance pathways.

I do consider this paper suitable to published in Cancers as soon as possible.

Incidentally, "tedizoled" should be changed into "tedizolid"

Reviewer 2 Report

This is an excellent review of Venetoclax in AML.

The study elaborates on the efficacy and safety of the agent compared to conventional chemotherapy for treatment of AML patients. Moreover, it gives a comprehensive overview of AML genetics and responses to Venetoclax. 

The authors discuss venetoclax in monocytic disease.  However, should the authors briefly mention specifically the impact of venetoclax on KMT2Ar leukemias (11q23)? Perhaps they could mention therapy-related AML. 

Venetoclax is now employed in post transplant setting. Should the authors talk about its role in this setting? 

Some of these AML cases can present with extramedullary disease. Should the author discuss about the role of venetoclax in CNS or extramedullary disease? It is nowadays used in r/r setting and readers would like to know more about this. 

 

 

Back to TopTop